Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil.
Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil.
复制标题
DOI：
10.1038/srep34165
复制
发表时间：
2016-10-31
影响因子：
4.6
通讯作者：
Kim Y
中科院分区：
文献类型：
--
作者：
Kim HY;Kim HV;Lee DK;Yang SH;Kim Y
阿尔茨海默病(AD)是一种神经退行性疾病，其特征是一系列病理事件的进展，如淀粉样蛋白β的聚集，然后是认知障碍的外在症状。鉴于不同治疗策略的组合通常在临床治疗的不同领域提供更快速和有效的结果，我们假设给予带有认知增强剂的抗淀粉样药物将在AD治疗中产生协同效应。在这里，我们联合使用4-(2-hydroxyethyl)-1-piperazinepropane-sulphonic酸(EPPS)(一种淀粉样蛋白清除化学物质)和多奈哌齐(一种乙酰胆碱酯酶抑制剂)来确定它们在AD治疗方面是否可以相互补充作用。我们发现，口服这两种分子会导致APP/PS1转基因小鼠认知能力的快速和持续改善。虽然没有证据表明有协同作用，但我们的结果表明，EPPS和多奈哌齐在不改变各自作用的情况下，功能是互补的。因此，联合使用改善疾病和缓解症状的药物可能是治疗AD的一种有前途的方法。
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by sequential progression of pathological events, such as aggregation of amyloid-β proteins, followed by outward symptoms of cognitive impairments. Given that a combination of different therapeutic strategies often provides more rapid and effective outcomes in diverse areas of clinical treatment, we hypothesized that administration of anti-amyloid drugs with cognitive enhancers would result in synergistic effects in AD treatment. Here, we co-administered 4-(2-hydroxyethyl)-1-piperazinepropane-sulphonic acid (EPPS), an amyloid-clearing chemical, and donepezil, an acetylcholinesterase inhibitor, to determine whether they could serve complementary roles for each other in regards to AD treatment. We found that oral administration of these two molecules led to a rapid and consistent cognitive improvement in APP/PS1 transgenic mice. Although there was no evidence for synergistic effects, our results indicated that EPPS and donepezil function complementary to each other without altering their individual effects. Thus, the combined use of disease-modifying and symptomatic relief drugs may be a promising approach in the treatment of AD.
登录
查看更多内容
DOI：
10.1056/nejmoa1304839
发表时间：
2014-01-23
期刊：
The New England journal of medicine
影响因子：
--
作者：
Salloway S;Sperling R;Fox NC;Blennow K;Klunk W;Raskind M;Sabbagh M;Honig LS;Porsteinsson AP;Ferris S;Reichert M;Ketter N;Nejadnik B;Guenzler V;Miloslavsky M;Wang D;Lu Y;Lull J;Tudor IC;Liu E;Grundman M;Yuen E;Black R;Brashear HR;Bapineuzumab 301 and 302 Clinical Trial Investigators
通讯作者：
Bapineuzumab 301 and 302 Clinical Trial Investigators
影响因子：
3.6
作者：
Li, Zhi;Herrmann, Konrad;Pohlenz, Frank
通讯作者：
Pohlenz, Frank
DOI：
10.1007/bf00403864
发表时间：
1971-01-01
期刊：
PSYCHOPHARMACOLOGIA
影响因子：
--
作者：
WRAY, SR;COWAN, A
通讯作者：
COWAN, A
影响因子：
48
作者：
Jack, Clifford R., Jr.;Knopman, David S.;Jagust, William J.;Shaw, Leslie M.;Aisen, Paul S.;Weiner, Michael W.;Petersen, Ronald C.;Trojanowski, John Q.
通讯作者：
Trojanowski, John Q.
影响因子：
4.8
作者：
Cao, Dongfeng;Lu, Hailin;Li, Ling
通讯作者：
Li, Ling